tirzepatide surmount-1 weight loss percent 72 weeks results I Was Right (and Wrong) About the Management Space Men before and after tirzepatide:
Description
Always consult Dr

Super happy so far

The FDA has not specifically studied or approved these lower doses

Additionally, it is not suitable for individuals with pancreatitis, diabetic retinopathy, kidney issues, gallbladder disease, severe gastroparesis, or type 1 diabetes

Surprisingly, the SURMOUNT-5 trial found that fewer people discontinued tirzepatide due to side effects (2.7%) compared to semaglutide (5.6%)

Im looking forward to the second month of treatment